Immune-mediated anti-leukemia effects, often termed graft-versus-leukemia (GvL), operate after bone marrow or blood cell transplants for acute lymphoblastic leukemia, acute myelogenous leukemia and chronic myelogenous leukemia. Sometimes the magnitude of this antileukemia effect exceeds that of high-dose anti-leukemia drugs and radiation and can result in leukemia cure. We analyzed leukemia relapse data after transplants for chronic lymphocytic leukemia (CLL) in this context. These data support the notion of a strong GvL effect in CLL. However, as most of these data are from studies of allotransplants, it is uncertain whether GvL operates in settings where the anti-leukemia effector cells and target CLL cells are genetically identical except for leukemiarelated mutations. It is also uncertain whether GvL is distinct from GvHD. These potential limitations have important implications on whether immune therapy of CLL will work in non-allotransplant settings.
Introduction
Chronic lymphocytic leukemia (CLL) is a clonal cancer of the immune system. Some aspects of immunity in CLL are paradoxical; for example, although persons with CLL have too many B-cells, they are immune deficient. Also, considerable data suggest that alterations in immune state moderate the course of CLL. The most convincing example is immune mechanisms associated with an allogeneic bone marrow or blood cell transplant following high doses of anti-leukemia drugs with or without radiation. Here, after adjusting for other predictive variables for leukemia relapse, persons developing graft-versus-host disease (GvHD) are said to be less likely to have recurrent CLL than those without GvHD (see below). Conversely, removing T-cells from an allograft is claimed to increase leukemia relapse risk even after adjusting with GvHD. These immune-mediated effects are collectively termed as graft-versus-leukemia (GvL). At this juncture we use the term GvL to indicate any immune-mediated anti-leukemia effect in a transplant recipient. Later we discuss whether GvL can be distinguished from GvHD and whether GvL can operate in settings where the anti-leukemia effector cells and target CLL cells are genetically identical except for mutations related to leukemia.
Although allotransplants after high-dose drugs with or without radiation cure rare persons with CLL, unlike other therapies, their use is relatively uncommon. One barrier to wider use of allotransplants is that people with CLL are typically too old (median age, 65 years). Attempts to expand use of allotransplants to these older persons include lowering doses of pretransplant anti-leukemia drugs and/or radiation (mini-or reduced intensity conditioning (RIC) allotransplants). Another approach to expanding transplants to older persons is autotransplants. There are, however, important caveats to using these approaches. As RIC allotransplants use lower doses of pretransplant drugs with or without radiation than conventional allotransplants, eradicating residual CLL cells in the recipient requires a potent immune-mediated GvL effect. Likewise, although autotransplants use high doses of drugs with or without radiation, they cannot cure CLL unless some immune perturbation concomitant with the transplant eradicates CLL cells unavoidably present in the graft.
As indicated, success of allo-and autotransplants depends on an effective anti-CLL GvL effect. Such an effect, if it exists, might also be used in a non-transplant setting to cure people with CLL. Here, we consider whether there are convincing data of an immune-mediated GvL effect in CLL. Our approach, similar to our strategy in acute lymphoblastic leukemia, acute myelogenous leukemia (AML) and chronic myelogenous leukemia, compared leukemia relapse risks in diverse transplant-related settings.
leukemia relapse risk of 10-20% after conventional allotransplants (namely allotransplants after high doses of anti-leukemia drugs with or without radiation). Furthermore, although leukemia relapse risk after autotransplants is continuous and un-ending, relapse risk after allotransplants is stable at 5-10 years. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Finally, allotransplants are effective in persons with advanced, drug-resistant CLL, 9,10 whereas autotransplants are not. 19 These striking differences in leukemia relapse risk pattern and activity after allo-and autotransplants might reflect one or more variables that differ between these groups including subject selection, an allogeneic versus autologous immune background, GvHD, leukemia contamination of the graft or combinations of these variables. Insight into which if any of these variables operate can be studied by comparing leukemia relapse risk in recipients of allotransplants with and without GvHD (see below).
RIC allotransplants
Data from RIC allotransplants in CLL also support an immune-mediated GvL effect. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Here, where relatively low doses of anti-leukemia drugs with or without radiation are given pretransplant, most of the anti-leukemia effect is likely from GvL associated or not with GvHD. Table 1 summarizes data from eight studies. Transplant-related mortality (TRM) was 7-26% and 2-year probability of relapse was 7-48%. Reasonable outcomes are also reported in persons with unfavorable leukemia prognostic factors like unmutated V H genes and/or 11q and 17p chromosome abnormalities. 25 Ritgen et al. 30 studied minimal residual leukemia (MRL) in nine subjects after RIC allotransplants. MRL kinetics were bi-phasic: a modest decrease in leukemia cells early after transplant followed by a marked reduction after about 3 months. Similarly, Schetelig et al. 20 reported disappearance of CD5/CD19 co-expressing cells (presumably CLL cells) only after about 4 months after transplant. Furthermore, Ritgen et al. 31 reported a stronger correlation between leukemia eradication and chronic GvHD and/or donor lymphocyte infusions (DLI; see below) than with pretransplant conditioning. Subjects in this study had a poor prognosis (unmutated V H genes) but responded favorably to a presumed GvL effect. This contrasts with data from autotransplants (see above) where molecular responses are rare.
Relationship between GvL and GvHD
In most studies of leukemia relapse after allotransplants, extensive chronic GvHD correlates with a lower leukemia relapse risk. This is especially so after allotransplants for AML and myelodysplastic syndrome; 1-4 similar trends are reported for lymphoma and CLL. 32 Dreger et al. 21 reported a correlation between chronic GvHD and likelihood of achieving complete remission after a conventional allotransplant: complete remission was achieved in 43 of 44 subjects developing chronic GvHD but only 14 of 33 subjects without chronic GvHD. Similarly, there was only one relapse among 37 evaluable subjects with chronic GvHD versus 19 relapses in 40 subjects without chronic GvHD. These data indicate that subjects with chronic GvHD are more likely to achieve complete remission and less likely to relapse than subjects without chronic GvHD.
In another study of time-dependent post-transplant correlates in allotransplant recipients with CLL, Sorror et al. 22 reported median intervals from transplant to onset of acute and chronic GvHD of 1.4 and 4.5 months. Median intervals from transplant to disappearance of pretransplant CLL-associated cytogenetic abnormalities, CD5/CD19-coexpressing CLL cells, enlarged lymph nodes and molecular evidence of CLL were 3-12 months. Although these data show a correlation between GvHD and anti-leukemia effects, they do not address causality. Likewise, onset of 
Transplants from genetically identical twins
Analysis of data of leukemia relapse risk among recipients of genetically identical twin transplants can quantify the anti-leukemia effects of pretransplant drugs and radiation of a potential GvL effect in a non-allogeneic setting. Unfortunately, such data are reported few in number. Pavletic et al. 34, 35 reported 19 subjects transplanted between 1980 and 2001 with bone marrow or blood cell transplants after high doses of pretransplant anti-leukemia drugs with or without radiation. Four of 13 subjects achieving complete remission relapsed with a 5-year cumulative relapse risk of 52% (95% confidence interval, 27-77%). Although the broad confidence interval precludes definitive interpretation, this rate seems higher than that after allotransplants but lower than after autotransplants. These data are consistent with a GvL effect. Other reports are of fewer cases and less informative.
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Donor lymphocyte infusions
Anti-leukemia effects of DLI on recurrent CLL are useful in evaluating whether or not there is a GvL effect. This is especially so after RIC allotransplants where GvL is needed for leukemia eradication. There are several reports of eradication of persistent and/or recurrent CLL after transplant. 18, [20] [21] [22] 28, 30, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Most report small numbers of subjects; only two had more than 10. 21, 28 Overall, 43 of 92 subjects responded; 35 achieved complete remission and eight partial remission. Although some responses were sustained, there was often insufficient follow-up for critical evaluation. Responses were best in subjects with fewer leukemia cells: about 50% in persons with MRL versus o20% in those with extensive CLL. Analysis of one report of an especially high response rate in advanced CLL after DLI is complicated by concomitant use of rituximab. 45 Similarly, more responses to DLI were seen after T-cell deplete versus T-cell replete RIC allotransplants. 18, 28, 48 These data are also compatible with reports of cases where tapering after transplant immune suppression correlated with a clinical anti-leukemia effect and onset of acute and/or chronic GvHD. 53 In summary, data from studies of DLI and modulation of posttransplant immune suppression support the notion of an allogeneic GvL effect in CLL.
T-cell responses after allotransplants
The role of T-cells in preventing relapses is suggested by the increased relapse rates after T-cell depleted allograft. 18 Gribben et al. reported data of donor CD4-and CD8-T-cell responses after transplant to CLL-specific immunoglobulin idiotype after RIC allotransplants. 54 Idiotype-specific Tcells were detected in 17 of 26 subjects, a median of 100 days after transplant. Increased response frequency coincided with subsequent development of chronic GvHD. These cells killed recipient CLL cells in vitro. Kollgaard et al. 49 analyzed the clonotype of CD8-T-cells following RIC allotransplants. They showed that an early dynamic phase is followed by the appearance of stable T-cell clonotypes several months after transplant coinciding with clinical anti-leukemia response. Data from these studies are consistent with the concept of GvL in CLL.
Conclusions and implications
The data we review support the notion of a strong GvL effect in CLL. Others have reached similar conclusions with less extensive analyses. 29, 34, 35 However, a more critical analysis of GvL in CLL requires considering detailed data from larger numbers of allograft recipients with and without GvHD, recipients of T-cell-depleted allograft and genetically identical twin transplant recipients.
Because of this probable GvL effect in CLL, conventional or RIC allotransplants offer the greatest likelihood of curing persons with CLL. Autotransplants may have some use but, because they lack a GvL effect, are unlikely to cure CLL. As most data supporting GvL in CLL are from studies of allotransplants, it is less certain that this anti-leukemia effect operates in settings where the antileukemia effector cells and target CLL cells are genetically identical except for mutations related to the leukemia. This potential limitation has strong implications on whether immune therapy of CLL will work in non-allotransplant settings.
The focus of our review is on the concept of GvL in CLL, not on the best therapy of CLL now or in the future. We are not unaware, however, of additional implications that might be drawn from our conclusions regarding GvL in CLL. For example, are alternative donor transplants likely to be better than HLA-identical sibling transplants because of more GvHD or are umbilical cord blood cell transplants likely to be worse because of less GvHD. In every clinical transplant setting studied to date it has not been possible to convincingly separate GvL effects from GvHD. We see no reason why this should differ in CLL but data are needed to study this question. Until such data are available it seems safest to consider GvL and GvHD in CLL highly confounded. Thus, the best transplant strategy for CLL, a complex interaction of TRM risk (including GvHD) and leukemia relapse risk, can only be determined in large randomized clinical trials.
Another controversial issue not addressed by our analysis is the best timing for a transplant in CLL. Although some reason that immune therapy is most likely to be effective when there are fewer leukemia cells, there are few convincing data that the GvL-mediated anti-leukemia effects of transplants are better when done earlier after adjusting for diverse biases including time-to-treatment, leukemia stage and subject attrition after failure of conventional therapies. Again, appropriate power randomized trials are needed to answer this question.
In conclusion, immune-mediated anti-leukemia effects in CLL offer a new therapy option in an otherwise uncurable cancer. Determining how best to use this modality is an important challenge.
